- Refining method of ciprofloxacin and meglumine hydrochloride thereof
-
The invention provides a preparation process of ciprofloxacin and meglumine thereof. The intermediate product DLSX07 is stirred at Branson ° C. 20% minutes and then sonicated until the solution is cloudy, stirred at room temperature for a period 30s, stirred at room temperature 3h, cooled and slowly added to distilled water, and filtered through suction filtration and filter cake vacuum drying to obtain a pale yellow powder, and 4% the KOH mixture is subjected to ultrasonic treatment 40 - 50 °C. 1. The process is performed by stirring 5h. NCS .t. The solution is cloudy. LC-MS / MS detection powder is deltafloxacin, distilled water is added, and meglumine is mixed to obtain a deltafloxacin meglumine salt. By optimizing the preparation process, the use of the organic solvent is reduced, the reaction time is shortened, and the ice bath and the addition of the interface carrier material contribute to the improvement of the yield.
- -
-
Paragraph 0026; 0031-0033; 0035-0036; 0038
(2021/10/27)
-
- A crystal form L of a delafloxacin meglumine salt and a preparation method thereof
-
The invention provides a crystal form L of a delafloxacin meglumine salt. An X-ray powder diffraction pattern has characteristic diffraction peaks at 2[theta] of about 5.9, 6.3, 7.9, 11.8, 12.6, 14.6,17.3, 17.6, 19.0, 20.4, 22.0, 23.1, 23.7, 24.1, 25.0, 2
- -
-
Paragraph 0031-0037; 0072; 0073; 0076; 0077
(2019/11/29)
-
- Preparation method of Delafloxacin and intermediates thereof
-
The invention relates to a preparation method of Delafloxacin and intermediates thereof. The method comprises the following steps: firstly, taking 3-chloro-2,4,5-fluorobenzoic acid (compound 1) as a raw material and reacting the raw material with thionyl
- -
-
-
- [...] Meglumine crystalline form I and its preparation method
-
The invention discloses a delafloxacin meglumine crystal form I, the powder X-ray diffraction pattern of which represented by 2thata has diffraction peaks at 5.9+/-0.2, 7.4+/-0.2, 7.9+/-0.2, 9.4+/-0.2, 11.8+/-0.2, 13.1+/-0.2, 14. 0+/-0.2, 14.2+/-0.2, 14.6
- -
-
Paragraph 0037-0038; 0040; 0041; 0043; 0045; 0048
(2017/08/31)
-
- Preparation method of high-purity delafloxacin meglumine salt
-
The invention relates to a method for refining a delafloxacin intermediate compound shown in a formula I. The method comprises the following steps: dissolving the compound in the formula I in a good solvent, mixing the compound with a poor solvent, heatin
- -
-
Paragraph 0034
(2017/04/27)
-
- Delafloxacin meglumine salt crystal form, and preparation method thereof
-
The invention relates to a delafloxacin meglumine salt novel crystal form, and a preparation method thereof. The delafloxacin meglumine salt novel crystal form is characterized in that characteristic diffraction peaks can be observed at 2theta of about 6.
- -
-
Paragraph 0028
(2017/01/02)
-
- Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs
-
Pharmaceutical compositions having improved dissolution profiles for drugs therein is disclosed.
- -
-
Page/Page column 2
(2008/06/13)
-
- Synthesis of the quinolone ABT-492: Crystallizations for optimal processing
-
ABT-492 has been under development at Abbott Laboratories as a quinolone antibiotic. A convergent syntheses was utilized to prepare the compound on a multi-kilogram scale. Difficulties in isolation of intermediates were overcome by developing control of t
- Haight, Anthony R.,Ariman, Sema Z.,Barnes, David M.,Benz, Nancy J.,Gueffier, Francoix X.,Henry, Rodger F.,Hsu, Margaret C.,Lee, Elaine C.,Morin, Larry,Pearl, Kurt B.,Peterson, Matthew J.,Plata, Daniel J.,Willcox, David R.
-
p. 751 - 756
(2012/12/22)
-